\documentclass[aspectratio=169]{beamer}
%\documentclass[handout]{beamer}

% language settings
%\usepackage{fontspec, polyglossia}
%\setdefaultlanguage{magyar}

% common packages
\usepackage{amsmath, multimedia, hyperref, color, multirow}
%\usepackage{graphicx}
\usepackage{xcolor}
\definecolor{BlueGreen}{cmyk}{0.85,0,0.33,0}
\usepackage{url}

% TikZ
\usepackage{tikz}
%\usetikzlibrary{arrows.meta, decorations.pathmorphing, decorations.pathreplacing, shapes.geometric,mindmap}
%\usetikzlibrary{shapes.geometric,fadings,bayesnet}

% beamer styles
\mode<presentation>{
%\usetheme{Madrid}
\usetheme{default}
%\usetheme{Antibes}
%\usecolortheme{beaver}
\usecolortheme{default}
%\usecolortheme{dove}
%\usefonttheme{structureitalicserif}
\setbeamercovered{transparent}
}
\setbeamertemplate{blocks}[rounded][shadow=true]
\AtBeginSubsection[]{
  \begin{frame}<beamer>{Contents}
    \tableofcontents[currentsection,currentsubsection]
  \end{frame}
}
%\useoutertheme[]{tree}

% title, etc
\title{NF-L and GFAP levels in drug treated 5xFAD mice}
\subtitle{}
\author{Attila Jones}
\date{}

\begin{document}

\titlepage

\begin{frame}{Introduction}
\begin{columns}[t]
\begin{column}{0.5\textwidth}

Treatments

\begin{enumerate}
  \item 5xFAD
  \begin{enumerate}
    \item Saline
    \item Amiloride
    \item HCQ
    \item HCQ nano
    \item R-HCQ
    \item S-HCQ
    \item TUDCA
  \end{enumerate}
  \item WT
  \begin{enumerate}
    \item Saline
    \item TUDCA
    \item DMSO
  \end{enumerate}
\end{enumerate}
\end{column}

\begin{column}{0.5\textwidth}

Experiments

\begin{itemize}
  \item NF-L \emph{in vivo} over 12 weeks
  \item NF-L in terminal plasma and CSF
  \item GFAP in terminal plasma
\end{itemize}
\end{column}
\end{columns}
\end{frame}

\begin{frame}{NF-L in vivo: WT vs 5xFAD}
\begin{center}
\includegraphics[scale=0.5]{../../../notebooks/2023-11-15-5xfad-nfl-gfap/named-figure/NF-L-in-vivo-wt-tg.pdf}
\end{center}
\end{frame}

\begin{frame}{NF-L in vivo: treatments, 5xFAD background}
\includegraphics[scale=0.4]{../../../notebooks/2023-11-15-5xfad-nfl-gfap/named-figure/NF-L-in-vivo-treatments-tg.pdf}
\end{frame}

\begin{frame}{Fold change of NF-L at 4 weeks relative to 0 week: linear and log
  scale}
\begin{columns}[t]
\begin{column}{0.6\textwidth}
  
\includegraphics[scale=0.4]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-stripplot-linear-log-scale.pdf}
\end{column}

\begin{column}{0.4\textwidth}
\begin{itemize}
  \item approx.~normally dist
  \item approx.~equal variance
\end{itemize}
\end{column}
\end{columns}
\end{frame}

%\begin{frame}{Progression: NF-L change at 4, 8, 12 weeks relative to 0 week}
\begin{frame}[plain]{}
\includegraphics[scale=0.4]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-stripplot-week-4-8-12-3panels.pdf}

\includegraphics[scale=0.4]{../../../notebooks/2023-11-15-5xfad-nfl-gfap/named-figure/NF-L-in-vivo-treatments-tg.pdf}
\end{frame}

\begin{frame}{Model}
  The effect of treatment $j$ relative to Saline treatment on NF-L fold change
  (week 0-$k$ change):
\begin{eqnarray}
  \frac{\mathrm{Nfl}_i \; | \; k \, \mathrm{week}}{\mathrm{Nfl}_i \; | \; 0 \,
  \mathrm{week}} &=& \beta_{\mathrm{Saline}} + \beta_{j} x_{ij} + \epsilon_i
  \\
  \epsilon_i &\sim& \mathcal{N}(0, \sigma)
\end{eqnarray}

Interpretation
\begin{description}
\item[$\beta_{j} = 0$] no effect, $H_0J$
\item[$\beta_{j} > 0$] adverse effect
\item[$\beta_{j} < 0$] desired effect
\item[$\beta_{j} = - \beta_{\mathrm{Saline}}$] full effect (desired)
\end{description}
\end{frame}

\begin{frame}{Conditional estimation of effect $\beta_j$ given a $k$-week of treatment $j$}
\begin{columns}[t]
\begin{column}{0.5\textwidth}

\includegraphics[scale=0.3]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-drugeffect-tg-week-4.pdf}
\end{column}

\begin{column}{0.5\textwidth}

\includegraphics<1>[scale=0.3]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-drugeffect-tg-week-8.pdf}
\includegraphics<2>[scale=0.3]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-drugeffect-tg-week-12.pdf}
\end{column}
\end{columns}

\end{frame}

\begin{frame}{Main results: 4 and 8 week treatment combined}
\begin{columns}[t]
\begin{column}{0.55\textwidth}

\includegraphics[scale=0.35]{../../../notebooks/2024-01-05-5xfad-nfl-frequentist/named-figure/nfl-drugeffect-tg-week-4-8.pdf}
\end{column}

\begin{column}{0.5\textwidth}

\includegraphics<2>[width=\columnwidth]{../../../resources/QPS/5xFAD-mouse/CO28152_Report_final-Fig20.png}
\end{column}
\end{columns}
\end{frame}

\begin{frame}
\includegraphics[scale=0.4]{../../../notebooks/2023-11-15-5xfad-nfl-gfap/named-figure/NF-L-in-vivo-treatments-tg.pdf}
\end{frame}

\end{document}

\begin{columns}[t]
\begin{column}{0.5\textwidth}
\end{column}

\begin{column}{0.5\textwidth}

\end{column}
\end{columns}
